Dr Reddy's gets 5 observations from US FDA for API unit at Hyderabad

File of Dr Reddy's
The US Food and Drug Administration (USFDA) has issued Form 483 with five observations to an active pharmaceutical ingredients (API) plant of Dr Reddy's Laboratories Limited.

In a Bombay Stock Exchange (BSE) filing on Friday, the company said plant-3 at Bollaram on the city outskirts has recieved these observations upon completion of an inspection.

"These observations are related to procedures and facility maintenance. We will address them comprehensively within the stipulated time," Dr Reddy's said in its BSE filing.

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel